187 related articles for article (PubMed ID: 28266887)
1. Strategies to optimize siRNA delivery to hepatocellular carcinoma cells.
Scarabel L; Perrone F; Garziera M; Farra R; Grassi M; Musiani F; Russo Spena C; Salis B; De Stefano L; Toffoli G; Rizzolio F; Tonon F; Abrami M; Chiarappa G; Pozzato G; Forte G; Grassi G; Dapas B
Expert Opin Drug Deliv; 2017 Jun; 14(6):797-810. PubMed ID: 28266887
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of small interfering RNAs/micro interfering RNA in hepatocellular carcinoma.
Farra R; Grassi M; Grassi G; Dapas B
World J Gastroenterol; 2015 Aug; 21(30):8994-9001. PubMed ID: 26290628
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
Varshosaz J; Farzan M
World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
[TBL] [Abstract][Full Text] [Related]
4. Small interfering RNA-mediated gene suppression as a therapeutic intervention in hepatocellular carcinoma.
Hajiasgharzadeh K; Somi MH; Shanehbandi D; Mokhtarzadeh A; Baradaran B
J Cell Physiol; 2019 Apr; 234(4):3263-3276. PubMed ID: 30362510
[TBL] [Abstract][Full Text] [Related]
5. Pokemon siRNA Delivery Mediated by RGD-Modified HBV Core Protein Suppressed the Growth of Hepatocellular Carcinoma.
Kong J; Liu X; Jia J; Wu J; Wu N; Chen J; Fang F
Hum Gene Ther Methods; 2015 Oct; 26(5):175-80. PubMed ID: 26356810
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor activity of KNTC2 siRNA in orthotopic tumor model mice of hepatocellular carcinoma.
Makita Y; Murata S; Katou Y; Kikuchi K; Uejima H; Teratani M; Hoashi Y; Kenjo E; Matsumoto S; Nogami M; Otake K; Kawamata Y
Biochem Biophys Res Commun; 2017 Nov; 493(1):800-806. PubMed ID: 28843857
[TBL] [Abstract][Full Text] [Related]
7. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
Wang D; Chang R; Wang G; Hu B; Qiang Y; Chen Z
Anticancer Agents Med Chem; 2017; 17(7):948-954. PubMed ID: 27671301
[TBL] [Abstract][Full Text] [Related]
8. Galactosylated polyaspartamide copolymers for siRNA targeted delivery to hepatocellular carcinoma cells.
Cavallaro G; Farra R; Craparo EF; Sardo C; Porsio B; Giammona G; Perrone F; Grassi M; Pozzato G; Grassi G; Dapas B
Int J Pharm; 2017 Jun; 525(2):397-406. PubMed ID: 28119125
[TBL] [Abstract][Full Text] [Related]
9. Theranostical nanosystem-mediated identification of an oncogene and highly effective therapy in hepatocellular carcinoma.
Guo Y; Wang J; Zhang L; Shen S; Guo R; Yang Y; Chen W; Wang Y; Chen G; Shuai X
Hepatology; 2016 Apr; 63(4):1240-55. PubMed ID: 26680504
[TBL] [Abstract][Full Text] [Related]
10. Tumor-penetrating codelivery of siRNA and paclitaxel with ultrasound-responsive nanobubbles hetero-assembled from polymeric micelles and liposomes.
Yin T; Wang P; Li J; Wang Y; Zheng B; Zheng R; Cheng D; Shuai X
Biomaterials; 2014 Jul; 35(22):5932-43. PubMed ID: 24746965
[TBL] [Abstract][Full Text] [Related]
11. EGFR-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma.
Gao J; Yu Y; Zhang Y; Song J; Chen H; Li W; Qian W; Deng L; Kou G; Chen J; Guo Y
Biomaterials; 2012 Jan; 33(1):270-82. PubMed ID: 21963149
[TBL] [Abstract][Full Text] [Related]
12. A small interfering RNA targeting vascular endothelial growth factor efficiently inhibits growth of VX2 cells and VX2 tumor model of hepatocellular carcinoma in rabbit by transarterial embolization-mediated siRNA delivery.
Zou Y; Guo CG; Yang ZG; Sun JH; Zhang MM; Fu CY
Drug Des Devel Ther; 2016; 10():1243-55. PubMed ID: 27069355
[TBL] [Abstract][Full Text] [Related]
13. The Role of Small Interfering RNAs in Hepatocellular Carcinoma.
Chen F; Zhang W; Gao X; Yuan H; Liu K
J Gastrointest Cancer; 2024 Mar; 55(1):26-40. PubMed ID: 37432548
[TBL] [Abstract][Full Text] [Related]
14. Lipid Nanoparticle Systems for Enabling Gene Therapies.
Cullis PR; Hope MJ
Mol Ther; 2017 Jul; 25(7):1467-1475. PubMed ID: 28412170
[TBL] [Abstract][Full Text] [Related]
15. RNA interference as therapeutics for hepatocellular carcinoma.
Xu C; Lee SA; Chen X
Recent Pat Anticancer Drug Discov; 2011 Jan; 6(1):106-15. PubMed ID: 21110827
[TBL] [Abstract][Full Text] [Related]
16. Targeted delivery of siRNAs against hepatocellular carcinoma-related genes by a galactosylated polyaspartamide copolymer.
Perrone F; Craparo EF; Cemazar M; Kamensek U; Drago SE; Dapas B; Scaggiante B; Zanconati F; Bonazza D; Grassi M; Truong N; Pozzato G; Farra R; Cavallaro G; Grassi G
J Control Release; 2021 Feb; 330():1132-1151. PubMed ID: 33212117
[TBL] [Abstract][Full Text] [Related]
17. RNA interference against granulin-epithelin precursor prevents hepatocellular carcinoma growth: its application as a therapeutic agent.
Park MY; Park YS; Nam JH
Int J Oncol; 2011 Oct; 39(4):853-61. PubMed ID: 21701774
[TBL] [Abstract][Full Text] [Related]
18. Galactose Derivative-Modified Nanoparticles for Efficient siRNA Delivery to Hepatocellular Carcinoma.
Huang KW; Lai YT; Chern GJ; Huang SF; Tsai CL; Sung YC; Chiang CC; Hwang PB; Ho TL; Huang RL; Shiue TY; Chen Y; Wang SK
Biomacromolecules; 2018 Jun; 19(6):2330-2339. PubMed ID: 29808997
[TBL] [Abstract][Full Text] [Related]
19. Polymer-Mediated Delivery of siRNAs to Hepatocellular Carcinoma: Variables Affecting Specificity and Effectiveness.
Farra R; Musiani F; Perrone F; Čemažar M; Kamenšek U; Tonon F; Abrami M; Ručigaj A; Grassi M; Pozzato G; Bonazza D; Zanconati F; Forte G; El Boustani M; Scarabel L; Garziera M; Russo Spena C; De Stefano L; Salis B; Toffoli G; Rizzolio F; Grassi G; Dapas B
Molecules; 2018 Mar; 23(4):. PubMed ID: 29597300
[TBL] [Abstract][Full Text] [Related]
20. Developing lipid nanoparticle-based siRNA therapeutics for hepatocellular carcinoma using an integrated approach.
Li L; Wang R; Wilcox D; Sarthy A; Lin X; Huang X; Tian L; Dande P; Hubbard RD; Hansen TM; Wada C; Zhao X; Kohlbrenner WM; Fesik SW; Shen Y
Mol Cancer Ther; 2013 Nov; 12(11):2308-18. PubMed ID: 23943805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
